CML Clinical Trials

CML Clinical Trials Database -

Cancer research is an area where new treatments are being explored for the prevention, diagnosis and treatment of different types of cancer. Researchers conduct so called "clinical studies" or "clinical trials" to improve treatment options for the patients of today and tomorrow. These studies are performed to investigate the biological mechanisms of the disease, to optimize the use of existing therapies or to test new forms of treatment or new drugs to find out whether they are more effective or better tolerated. For more information please read our manual "what are clinical trials?"

Patients wishing to participate in clinical studies often look for a central source of information where they can find easy-to-understand facts on ongoing trials. CML Advocates Network is now hosting an inofficial database of current CML trials which have been initiated by academia (universities) or by pharmaceutical companies. This database is run by patients for patients and is set up as a dynamic register in which data are updated on an ongoing basis. CML Advocates Network has taken utmost care to verify the data entered, however, cannot assume any liability for the accuracy or completeness of the information. Patients should consult their doctor for personal advice and/or their scientific contact/study staff for the most up-to-date study information.

Do you know of any study that is not yet listed here? Please let us know by filling out this form. Or is there an entry which should be corrected? If so, please send us an email. Please also visit our forum if you have any questions or wish to share your experience on these studies.

CML Clinical Trials Database

3. Therapy optimization trials

1 OPTIC = Ponatinib in resistant chronic phase CML
Updated: 12 September 2016
2 Pioglitazone and TKI [USA]
Updated: 4 October 2016
3 DasaHIT = Dasatinib Holiday for Improved Tolerability [Germany]
Updated: 25 January 2017
4 DECLINE = Imatinib versus nilotinib in CML in chronic phase
Updated: 30 November 2016
5 Ruxolitinib for CML with minimal residual disease
Updated: 13 February 2015

4. Treatment of advanced phases

1 CA180-357 = Decitabine + Dasatinib for Blast Phase CML
Updated: 20 March 2015

5. Treatment discontinuation trials

1 LAST Stopping Tyrosine kinase inhibitors
Updated: 11 December 2015
2 ENESTPath Patient's Voice Italian Substudy [Italy]
Updated: 15 February 2016
3 MSIT = Malaysia Stop Tyrosine Kinase Inhibitor Trial
Updated: 11 December 2015

7. Other trials

1 PONDEROSA [Germany]
Updated: 27 January 2017
2 EUREKA = ELN registry
Updated: 12 March 2015
3 Eltrombopag for thrombocytopenia in CML
Updated: 12 February 2015
4 CA180-373 = A Phase 1B Study with Dasatinib plus Nivolumab in CML
Updated: 13 December 2015
5 LEONIDAS = Quality-of-Life effects of imatinib and dasatinib in CML
Updated: 20 October 2015

8. Other haematological trials (not CML)

1 DACOTA = Decitabine with or without Hydroxyurea versus Hydroxyurea in CMML[Europe]
Updated: 4 November 2015